JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids

  • 0Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Bmc Cancer +

|

April 11, 2025

|

April 11, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) can predict immunotherapy efficacy in non-small cell lung cancer (NSCLC). A high SII/ALB ratio indicates a poorer prognosis for NSCLC patients receiving immune checkpoint inhibitors and opioids.

Area Of Science

  • Oncology
  • Immunotherapy
  • Biomarkers

Background

  • Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer-related mortality.
  • Immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment.
  • Predictive biomarkers are crucial for optimizing ICI therapy and patient outcomes.

Purpose Of The Study

  • To evaluate the predictive value of pretreatment neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and systemic immune-inflammation index/albumin ratio (SII/ALB) for immunotherapy prognosis and efficacy.
  • To assess these ratios in NSCLC patients treated with ICIs and opioids.

Main Methods

  • Retrospective analysis of 78 NSCLC patients treated with ICIs and opioids.
  • Determination of optimal cut-off values using receiver operating characteristic (ROC) curves.
  • Univariate and multivariate analyses to assess the impact of NLR, PLR, and SII/ALB on patient prognosis.

Main Results

  • Both NLR and PLR demonstrated predictive value for treatment efficacy.
  • An SII/ALB ratio greater than 17.79 was identified as an independent risk factor for worse patient outcomes.

Conclusions

  • PLR and SII/ALB possess predictive value for immunotherapy efficacy in NSCLC patients.
  • NLR did not show significant predictive value in this cohort.
  • An SII/ALB ratio exceeding 17.79 is indicative of a poor prognosis for NSCLC patients undergoing immunotherapy with ICIs and opioids.

Keywords: